Comments
Loading...

Aprea Therapeutics

APRENASDAQ
Logo brought to you by Benzinga Data
$2.86
-0.15-4.98%
At Close: -
$2.85
-0.0098-0.34%
After Hours: 4:32 PM EDT
15 minutes delayed
Consensus Rating1
Buy
Highest Price Target1
$20.00
Lowest Price Target1
$2.00
Consensus Price Target1
$10.60

Aprea Therapeutics (NASDAQ:APRE) Stock, Analyst Ratings, Price Targets, Forecasts

Aprea Therapeutics Inc has a consensus price target of $10.6 based on the ratings of 5 analysts. The high is $20 issued by HC Wainwright & Co. on August 12, 2024. The low is $2 issued by HC Wainwright & Co. on March 16, 2022. The 3 most-recent analyst ratings were released by Wedbush, HC Wainwright & Co., and HC Wainwright & Co. on August 13, 2024, August 12, 2024, and June 24, 2024, respectively. With an average price target of $17 between Wedbush, HC Wainwright & Co., and HC Wainwright & Co., there's an implied 496.45% upside for Aprea Therapeutics Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
1
Mar
0
0
0
0
May
0
0
0
0
Jun
1
Aug
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
3.1
Hold
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Wedbush
HC Wainwright & Co.
Maxim Group
HC Wainwright & Co.
RBC Capital

1calculated from analyst ratings

Analyst Ratings for Aprea Therapeutics

Data brought to you by Benzinga APIs

FAQ

Q

What is the target price for Aprea Therapeutics (APRE) stock?

A

The latest price target for Aprea Therapeutics (NASDAQ:APRE) was reported by Wedbush on August 13, 2024. The analyst firm set a price target for $11.00 expecting APRE to rise to within 12 months (a possible 285.94% upside). 8 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Aprea Therapeutics (APRE)?

A

The latest analyst rating for Aprea Therapeutics (NASDAQ:APRE) was provided by Wedbush, and Aprea Therapeutics reiterated their outperform rating.

Q

When was the last upgrade for Aprea Therapeutics (APRE)?

A

There is no last upgrade for Aprea Therapeutics

Q

When was the last downgrade for Aprea Therapeutics (APRE)?

A

There is no last downgrade for Aprea Therapeutics.

Q

When is the next analyst rating going to be posted or updated for Aprea Therapeutics (APRE)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Aprea Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Aprea Therapeutics was filed on August 13, 2024 so you should expect the next rating to be made available sometime around August 13, 2025.

Q

Is the Analyst Rating Aprea Therapeutics (APRE) correct?

A

While ratings are subjective and will change, the latest Aprea Therapeutics (APRE) rating was a reiterated with a price target of $11.00 to $11.00. The current price Aprea Therapeutics (APRE) is trading at is $2.85, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch